While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner ...

Massachusetts General Hospital's 2025 MGH ALS Young Investigator Awards went to three scholars doing ALS research.

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

Precision Care Medicine students work with clinical faculty at Johns Hopkins Medicine to learn how to use machine learning ...

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell ...

Clene will soon meet with the Food and Drug Administration to discuss analyses that could support an application for ...

QurAlis' FlexASO® platform was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to ...

PRESS RELEASE MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN ...

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, ...

Kolar Toyota ALS Fishing Tournament at the end of May includes a panel to talk about hopeful advancements in research.

Neurodegenerative disorders, including Alzheimer’s Disease, Huntington’s Disease, Parkinson’s Disease, and Lou Gehrig’s Disease (ALS), pose considerable ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet. This is ...